Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.

Garber ST, Sivakumar W, Schmidt RH.

J Neurosurg. 2012 May;116(5):1093-6. doi: 10.3171/2012.2.JNS112132. Epub 2012 Mar 6.

PMID:
22394293
2.

Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.

Brunetti L, Chen C, White J.

Consult Pharm. 2014 Mar;29(3):169-78. doi: 10.4140/TCP.n.2014.169. Review.

PMID:
24589766
3.

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.

Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30.

4.

Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.

Augoustides JG.

J Cardiothorac Vasc Anesth. 2011 Dec;25(6):1208-12. doi: 10.1053/j.jvca.2011.08.005. Epub 2011 Oct 7. Review.

PMID:
21982327
5.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
6.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

7.

Preventing cardioembolic stroke in atrial fibrillation with dabigatran.

Weimar C, Hohnloser SH, Eikelboom JW, Diener HC.

Curr Neurol Neurosci Rep. 2012 Feb;12(1):17-23. doi: 10.1007/s11910-011-0229-4. Review.

PMID:
21960064
8.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
9.

Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.

[No authors listed]

Prescrire Int. 2012 Feb;21(124):33-6. Review.

PMID:
22413715
10.

Potential inaccuracy of point-of-care INR in dabigatran-treated patients.

Baruch L, Sherman O.

Ann Pharmacother. 2011 Jul;45(7-8):e40. doi: 10.1345/aph.1Q105. Epub 2011 Jun 28.

PMID:
21712509
11.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
12.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

13.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hamm├Ęs F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

14.

Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.

Moore CH, Snashall J, Boniface K, Scott J.

Am J Emerg Med. 2012 Nov;30(9):2082.e1-2. doi: 10.1016/j.ajem.2011.10.031. Epub 2011 Dec 23.

PMID:
22196949
15.

Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.

Bendel SD, Bona R, Baker WL.

Adv Ther. 2011 Jun;28(6):460-72. doi: 10.1007/s12325-011-0025-1. Epub 2011 Apr 26. Review.

PMID:
21533567
16.

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.

Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.

Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.

17.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
18.

Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

Escobar C, Barrios V, Jimenez D.

Cardiovasc Ther. 2010 Oct;28(5):295-301. doi: 10.1111/j.1755-5922.2010.00216.x. Epub 2010 Aug 16. Review.

PMID:
20718760
19.

Dabigatran, intracranial hemorrhage, and the neurosurgeon.

Awad AJ, Walcott BP, Stapleton CJ, Yanamadala V, Nahed BV, Coumans JV.

Neurosurg Focus. 2013 May;34(5):E7. doi: 10.3171/2013.2.FOCUS1323. Review.

PMID:
23634926
20.

Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.

Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW.

J Med Toxicol. 2011 Dec;7(4):281-7. doi: 10.1007/s13181-011-0178-y. Review.

Supplemental Content

Support Center